TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Botox for the Treatment of Recurrent Chronic Exertional Compartment Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to provide written informed consent~* Willing to comply with all study procedures and be available for the duration of the study~* Documented diagnosis of R-CECS determined with elevated compartmental pressure testing following lower extremity fascia release (fasciotomy or fasciectomy)~* Females of childbearing potential must have a negative urine pregnancy test prior to enrollment and agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to randomization, for the duration of study participation, and for 7 days following completion of therapy.~  * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:~    * Has not undergone a hysterectomy or bilateral oophorectomy; or~ * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).~Exclusion Criteria:~* History of hypersensitivity or allergy to any of the study drugs or drugs of similar chemical classes~* Known neuromuscular disease~* Known pulmonary disease including but not limited to asthma, pneumonia, or upper respiratory tract infection~* Dysphagia~* Known cardiac disease including but not limited to congestive heart failure, arrhythmia, or history of myocardial infarction~* Enrolled in another clinical trial or has used of any investigational drugs, biologics, or devices within 30 days prior to enrollment~* Currently or have taken in the past medications that affect neuromuscular function, aminoglycosides, muscle relaxants, or other botulinum neurotoxin agents. Currently taking any blood-thinning medications including, but not limited to Plavix, Coumadin, Eliquis, Xarelto~* Women who are pregnant or breast-feeding~* Vulnerable populations~* Not suitable for study participation due to other reasons at the discretion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with R-CECS (Type: EXPERIMENTAL): Botox to be injected under standard palpatory technique into the affected lower leg compartment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Schizophrenia~* 18-65 years~* No hospitalization for an exacerbation of schizophrenia within two months prior to screening and during the screening period~Exclusion Criteria:~* Subjects who are acutely psychotic or subjects with current Axis I primary psychiatric diagnosis other than schizophrenia~* At significant risk of suicide, and the potential for violent behavior (likely to harm themselves or others) based on history

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient ≥ 18 years of age with documented chronic hepatitis C virus infection of genotype 1a undergoing liver transplantation from either a deceased donor or living donor.~* Patient or legal guardian/health care proxy must have read, understood and provided written informed consent and HIPAA authorization after the nature of the study has been fully explained.~Exclusion Criteria:~* Positive serology for Hepatitis B surface Antigen~* Positive serology for HIV~* Pregnancy or breastfeeding~* Previous history of any organ transplant~* Planned receipt of combined organ transplant (e.g. liver and kidney)~* Receipt or planned receipt of immune globulin (IVIG) within 90 days of enrollment~* History of extrahepatic malignancy and/or receiving chemotherapy within 90 days prior to enrollment with the exception of chemoembolization for hepatocellular carcinoma~* Hepatocellular carcinoma with tumor burden outside of the Milan criteria~* History of chronic renal insufficiency or creatinine \> 2.5 for ≥ six months~* Personal or family history of deep venous thrombosis or pulmonary embolism~* Receipt of liver allograft from HCV positive donor or Hepatitis B core antibody positive donor~* Receipt of liver allograft donated after cardiac death of donor~* Receipt of any antiviral agents, licensed or investigational for hepatitis C virus within 90 days prior to enrollment~* Receipt of any other investigational study product within 30 days prior to enrollment~* Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the patient participating in the study or make it unlikely that the patient could complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MBL-HCV1 (Type: EXPERIMENTAL): None
- 0.9% sodium chloride (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 13-22 years of age at time of enrollment~* Moderate-severe self-reported symptoms of depression at baseline (PHQ-8 \>=5)~* Under the care of a US-based healthcare provider and willing and able to provide the name and contact information of the provider during consent~* English fluency or proficiency and literacy of adolescent and consenting legal guardian, if required~* Access to an eligible mobile device (capable of installing the app) and regular internet access~* Willing to provide informed e-consent/assent and have legal guardian willing to provide informed e consent (if required)~Exclusion Criteria:~* Change in concurrent treatment (medication, and/or psychotherapy) for depression 30 days prior to study enrollment~* Suicide attempt within the past year~* Active suicide ideation with intent~* Previously participated in user testing or clinical testing of the Spark app~* Any condition, comorbidity, or event that, in the opinion of the investigator, will prevent the participant from adhering to the protocol or benefitting from the treatment (e.g., unable to perform informed assent or consent, treatment resistance as determined by investigator) or will prevent investigators from being able to ensure safety (e.g., will be leaving the country during study time period)

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- SparkRx Mobile App (Type: OTHER): The 5-week SparkRx app is divided into 5 levels intended to be completed weekly. A character called 'Limbot' is used as a guide. Limbot encourages the user in completing the behavioral activation program and provides personal examples of how they have undertaken behavioral activation therapy. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and Participant Symptom Check (PSC) questionnaire in the mobile app. Tasks in the mobile app progress in a linear fashion-- i.e., each task must be completed to progress to the next task. Certain on-demand resources can be accessed in the app at any time, including crisis resources. Text entries that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Invasive mechanical ventilation expected to be required more than 48 hours~* Nutrition started within 24 hours after initiation of endotracheal mechanical ventilation~* Treatment with vasoactive drug administered via a central venous catheter~* Age over 18 years~* Signed information~Exclusion Criteria:~* Abdominal surgery within 1 month before inclusion~* History of esophageal, gastric, duodenal or pancreatic surgery~* Bleeding from the esophagus, stomach or bowel~* enteral nutrition via gastrostomy or jejunostomy~* pregnancy~* Treatment-limitation decisions~* Current inclusion in a trial on comparison between enteral and parenteral nutrition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parenteral nutrition (Type: OTHER): Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level \< 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
- Enteral nutrition (Type: OTHER): Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Caffeine in Children With Obstructive Sleep Apnea, Dose Response Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children with OSA and/or increased end tidal C02 (sleep related hypoventilation, obstructive hypoventilation or sustained alveolar hypoventilation), 2-12 years of age, and both genders will be eligible to be part of the study. OSA and its severity will be diagnosed by a preoperative polysomnography.~Exclusion Criteria:~* Children with compromised cardiovascular, pulmonary or renal function, those with congenital syndromes, sickle cell disease, history of seizures and those receiving theophylline will be excluded.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Caffeine and Sodium Benzoate 10 mg/kg IV (Type: EXPERIMENTAL): Group 1 of randomized study.
- Caffeine and Sodium Benzoate 20 mg/kg IV (Type: EXPERIMENTAL): Group 2 of randomized study
- 0.9 NS Saline (Type: PLACEBO_COMPARATOR): Control group of randomized study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Clinical Outcomes of Targeted Radiofrequency Ablation and Kyphoplasty (Also Known as Vertebral Augmentation) to Treat Painful Metastatic Vertebral Body Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* One to 2 painful vertebrae (T1-L5) with evidence of osteolytic metastatic lesion with known primary histology with pathologic fracture(s) at index vertebra by MRI~* Pain score ≥ 4 on the numerical rating pain scale~* Life expectancy of ≥ 6 months~Exclusion Criteria:~* Primary tumors of the bone at index vertebra~* Benign tumors of the bone at index vertebra~* Osteoblastic tumors at index vertebra~* Index vertebra with more than one (1) pedicle involved~* Epidural extension of tumor within 5 mm of the spinal cord or without sufficient room for thermal protective maneuvers~* Spinal cord compression or canal compromise requiring decompression~* Radiation therapy is planned to be started on the index vertebra within 4 weeks post procedure~* Radiation therapy was performed on the index vertebra within 2 months before enrollment~* Major surgery of the spine was performed within 3 months before enrollment~* Index vertebra(e) had previous spine surgery including vertebroplasty or kyphoplasty~* Additional non-kyphoplasty/vertebroplasty surgical treatment is required for the index vertebra

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RF Ablation and Vertebral Augmentation (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed soft tissue sarcoma (STS) for which neoadjuvant or adjuvant radiotherapy is considered standard care~  * Stage IB-III disease~ * Primary or locally recurrent disease~* The following chemotherapy-sensitive STS histologies are excluded:~  * Primitive neuroectodermal tumor~ * Desmoplastic small round cell tumor~ * Synovial sarcoma~ * Myxoid round cell liposarcoma~ * Angiosarcoma~* No sarcomas for which surgical staging and adjuvant radiotherapy are considered standard care (e.g., uterine sarcomas, including leiomyosarcoma, malignant mixed Müllerian tumors, and endometrial stromal sarcoma)~* No retroperitoneal STS~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Able to complete the self-assessment questionnaires (may use translator service)~* Willing and able to undergo pre-treatment core needle biopsies~* Negative pregnancy test~* No known HIV positivity~PRIOR CONCURRENT THERAPY:~* Prior adjuvant chemotherapy for STS allowed provided patient has locally recurrent disease~  * At least 1 year since prior adjuvant chemotherapy~* No prior radiotherapy to the site of present STS~* No other concurrent cytotoxic chemotherapy, targeted therapy, or investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): pre-operative radiation + surgery PTV will receive a total dose of 50 Gy in 25 fractions, 2 Gy per fraction, 5 fractions per week, over approximately 5 weeks. Concurrently, the GTV2, if present, will receive 54 Gy in 25 fraction. Dose will be prescribed to the isodose volume that encompasses the PTV. All patients will be treated by 6 MV photon beam.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering from non-small cell lung cancer (NSCLC) with clinical stage IIIB and IV tumours~* Patients with one chemotherapy regimen (first line treatment) (adjuvant chemotherapy following surgery is also regarded as first line treatment)~* Patients who are in transition from first to second line treatment~* Patients who signed an informed consent~Exclusion Criteria:~* Chemotherapy naïve patients~* Patients ever enrolled in clinical studies treating non-small cell lung cancer (NSCLC) with chemotherapy (during 1st and 2nd line chemotherapy)~* Patients who ever had chemotherapy for an indication other than NSCLC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Regular treatment for non-small cell lung cancer (NSCLC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Acupuncture Care for Breast Cancer Patients Experiencing Side Effects From Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females, 18 years or older with early stage breast cancer, no previous chemotherapy and no metastatic disease~Exclusion Criteria:~* Needle phobia, use of anticoagulant drugs, inability to comply with study regimen

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- acupuncture therapy (Type: EXPERIMENTAL): Breast cancer patients are randomised to additional 12 acupuncture treatment sessions while undergoing standard chemotherapy
- Usual care (Type: OTHER): Control group (usual care) receives standard chemotherapy alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age Phase 1: ≥ 18 years to ≤ 55 years Phase 2: ≥ 18 years to ≤ 65 years~2. Are male or non-pregnant females who agree to contraceptive requirements.~3. Patients with RT-PCR confirmed COVID-19 in ≤ 72 hours prior to randomization \[Ct ≥ 24\].~4. Have SpO2\<94% (range 90-93%) on room air.~5. Have one or more of the following- dyspnea, fever, cough, respiratory rate ≥ 24 per minute and heart rate up to 120 per minute.~6. Patients who agree to participate in the study and follow all study related procedures~Exclusion Criteria:~1. Require mechanical ventilation~2. Have oxygen saturation less than or equal to 89 percent~3. Patients re-infected with SARS-CoV-2~4. Suspected or proven serious active bacterial fungal viral or other infection~5. Patients with positive skin test with IP~6. Patients with known equine allergies or past medical history of serum sickness~7. Patient who are HIV, HCV, HbsAg positive or immunocompromised~8. Patients with significant co-morbidities at screening~9. Moribund state~10. Pregnant or nursing women~11. Participating in other clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Equine COVID-19 Antiserum [F(ab')2] (BSVEQAb) Along with Standard of care (Type: EXPERIMENTAL): Dose of BSVEQAb - 5 mg/kg or 10 mg/kg body weight. It is administered as a single dose intravenously after diluting in 100 -150 ml saline. The infusion will be done over 1 to 2 hours.~Standard of care for treatment of COVID-19 positive patients
- Standard of care. (Type: ACTIVE_COMPARATOR): Treatment as per current treatment guidelines and institutional practice for COVID-19 positive patients will be administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically confirmed metastatic well differentiated Neuroendocrine Tumour (NET) (Grade G1 or G2 according to the World Health Organisation 2010 classification): Gastro-entero-pancreatic (GEP) or Bronchopulmonary (BP) primary tumour, or tumour of unknown origin believed to be of GEP origin, if a primary tumour elsewhere was excluded by multiphasic computerised tomography (CT) or magnetic resonance imaging (MRI)~* Disease progression radiologically documented with evaluable imaging (CT or MRI, digital or print-out), performed within 12 months and within 6 months prior to the first PRRT/LAN ATG cycle~* Metastatic- or locally-advanced, hormonal functioning or nonfunctioning GEP-NET or BP-NET;~* Confirmed presence of Somatostatin Receptors (SSTRs) on all target lesions based on positive SSTR scintigraphy (Octreoscan®/99mTC-tektrotyd) or 68Ga SSTR Positron Emission Tomography-Computerised Tomography (PET/CT) imaging, i.e. Grade ≥2 respectively per the Krenning scale or per the modified Krenning scale~Exclusion Criteria:~* Absence of information regarding LAN ATG treatment: dose received, start date, frequency of injections~* No CT or MRI within 12 months and within 6 months preceding the baseline, or at the end of the last PRRT/LAN ATG cycle~* Absence of information on cumulative activity of PRRT with 177 Lutetium (177Lu) DOTATOC or 177Lu-DOTATATE received (at least 500 mCi (equivalent to 18.5 GBq), for the entire therapy)~* PRRT prior to the first combination cycle of PRRT/LAN ATG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues